| Old Articles: <Older 8041-8050 Newer> |
|---|
 |
The Motley Fool
November 8, 2011
Brian Orelli |
This Biotech Thinks It's Cheap Amgen thinks its investors aren't valuing the company properly. It's offering to repurchase $5 billion worth of stock -- about 10% of its value -- and even willing to borrow the cash to get it done.   |
The Motley Fool
November 8, 2011
Anders Bylund |
Isis Pharmaceuticals' Shares Plunged: What You Need to Know Shares of drug developer Isis Pharmaceuticals hardly looked like a model of fertility today as they fell 10.5% in heavy intraday trading. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
November 8, 2011
Brandon Glenn |
Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity. |
The Motley Fool
November 7, 2011
David Williamson |
Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals... |
The Motley Fool
November 7, 2011
Dan Caplinger |
Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development. |
The Motley Fool
November 5, 2011
David Williamson |
Inhibitex Investors: Why Shares Popped 115% Great results for INX-189 send shares skyward. |
The Motley Fool
November 4, 2011
Brian Orelli |
You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason. |
The Motley Fool
November 4, 2011
Anders Bylund |
Optimer Pharmaceuticals Shares Dropped: What You Need to Know Shares of Optimer Pharmaceuticals, which develops advanced hospital products such as highly specialized antibiotics, fell as much as 15.7% today on very heavy trading. |
The Motley Fool
November 4, 2011
Luke Timmerman |
Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement. |
| <Older 8041-8050 Newer> Return to current articles. |
